Press release
Lonza and ORGANOBALANCE Enter Global License Agreement to Develop and Market Unique Probiotic, Lactobacillus Anti-H. pylori
Basel, Switzerland and Berlin, Germany, 19 April 2011 – Lonza and ORGANOBALANCE today announced the signing of a worldwide exclusive license agreement in which Lonza will develop, produce and commercialize products containing a probiotic Lactobacillus strain. Developed by ORGANOBALANCE GmbH, the probiotic strain acts against Helicobacter pylori (H. pylori). Research shows that H. pylori has been implicated as a common cause of peptic ulcers and gastritis.Currently, about 50 percent of the global population is infected with H. pylori (Source: Czinn SJ. J Pediatr. 2005 Mar;146 (3 Suppl):S21-6.). However, this new probiotic strain demonstrates great potential in helping to maintain a balanced H. pylori concentration. Utilizing a unique patent-protected mode of action, Lactobacillus anti-H. pylori binds to H. pylori in the stomach, thus creating large aggregates, which are subsequently flushed out of the stomach and excreted.
“This agreement with ORGANOBALANCE creates a basis for Lonza to enter the probiotic market - a market with vast growth potential - with a unique ingredient,” said Roman Quinter, Senior Vice President and Head of Nutrition Ingredients business for Lonza. “Lonza is a global leader in the manufacturing of intermediates and API’s for the pharmaceutical industry through biotechnology and fermentation. Integrating the Lactobacillus Anti-H. pylori strain into our nutrition ingredient portfolio provides an opportunity to leverage our strong biotech expertise and knowledge to provide a highly effective product to the nutrition landscape.“
Produced via a fermentation process, the Lactobacillus anti-H. pylori strain is patent-protected. The strain demonstrates probiotic activity by gently, yet highly effectively, removing H. pylori from the stomach.
“As the leader in the development of innovative probiotic strains, we regard this agreement with Lonza as a further recognition of ORGANOBALANCE’s strategy, our expertise, and our innovative capacity,” said Prof. Dr. Christine Lang, CEO of ORGANOBALANCE GmbH. “We highly appreciate Lonza’s dedication to lead our development into great success on the nutrition marketplace.”
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.
About ORGANOBALANCE
ORGANOBALANCE GmbH is a company specialising in strain development and microbiological screening, tapping the potential of beneficial microorganisms, known as specific probiotic cultures, in order to balance out the microflora and restore the microbial equilibrium in a natural way. In close cooperation with renowned industry partners, ORGANOBALANCE GmbH develops new biological products in the fields of pharmaceutics, preventive health care, nutrition and cosmetics. In its development activities the company draws on its own collection of more than 8000 microorganisms suitable for use in foodstuffs as well as its own OASSYS® screening systems. ORGANOBALANCE was founded in 2001 and is based in Berlin, Germany. More information can be found at www.organobalance.com.
Lonza Ltd
Marketing Manager Nutrition
Adriana Williams
Tel +41 61 316 8626
Fax + 41 61 316 9626
adriana.williams@lonza.com
Lonza Group
Head of External Communications
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com
ORGANOBALANCE GmbH
Kristin Ebert
Gustav-Meyer-Allee 25
13355 Berlin
Germany
Tel +49 30 46307-200
Fax +49 30 46307-210
info@organobalance.com
www.organobalance.com
Press contact for ORGANOBALANCE GmbH:
COMAGO
Communication . Marketing . Organisation
Helmut Landenberger
Wiesenstrasse 55
14612 Falkensee
Germany
Tel +49 33 22 84 06 52
Fax +49 33 22 84 06 53
mail@comago.de
www.comago.de
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lonza and ORGANOBALANCE Enter Global License Agreement to Develop and Market Unique Probiotic, Lactobacillus Anti-H. pylori here
News-ID: 171597 • Views: …
More Releases from ORGANOBALANCE GmbH
Increasing the Potential for Yeast Strains in Biotech Manufacturing
ORGANOBALANCE to present its latest research findings at ACHEMA 2012
Berlin, 13 June 2012 – At this year's ACHEMA (Frankfurt,18 to 22 June), the Berlin-based biotech company ORGANOBALANCE GmbH will present its most recent findings on the potential uses of yeast strains in the biotechnological production of fine chemicals and new ingredients for pharmaceuticals, cosmetics, foods or feedstuffs (metabolic engineering of yeasts).
In his talk, The yeast Saccharomyces cerevisiae as platform organism…
ORGANOBALANCE Signs Licensing Agreement with Sanofi Pasteur
Modified strain of yeast paves way for new industrial vaccine production process
Berlin, 11 January 2012 – The company ORGANOBALANCE GmbH, Berlin, Germany, today announced the conclusion of a licensing agreement with Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY). This will provide Sanofi Pasteur with access to a modified yeast strain (Saccharomyces cerevisiae, more commonly known as baker's yeast) for use in vaccines. By signing the…
ORGANOBALANCE to present latest research findings at the BIOTECHNICA Trade Show …
Berlin-based company to intensify efforts in contract research and white biotechnology
Berlin, September 28, 2010 – Once again this year, ORGANOBALANCE will present current projects and latest research findings to an international audience of experts at the BIOTECHNICA Trade Show taking place in Hannover, Germany from October 5 to 7, 2010.
Since 2001, the Berlin-based company has been doing research - primarily for clients from the fields of red, white and green…
ORGANOBALANCE Announces Substantial Investment
Dr Bernd Wegener to invest in Berlin (Germany) Biotech company
Berlin (Germany), 17 June 2010 – ORGANOBALANCE GmbH Berlin and Bernd Wegener DVM, PhD (Chairman of the Board of the German Federal Association of the Pharmaceutical Industry), have announced the completion of an investment agreement which shall take immediate effect. Aside from detailing a financial commitment, the agreement also foresees an active role for Dr Wegener in a position of responsibility…
More Releases for Lonza
Biotin Market is Booming Worldwide | DSM, Lonza, BASF
HTF MI just released the Global Biotin Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major companies profiled in Biotin Market are:
DSM, Lonza, BASF, Zhejiang Medicine,…
Culture Media Market | Global and Regional Analysis and Forecast 2027 | Merck & …
Culture Media Market describes an in-depth evaluation and Covid19 Outbreak study on the present and future state of the Culture Media market across the globe, including valuable facts and figures. Culture Media Market provides information regarding the emerging opportunities in the market & the market drivers, trends & upcoming technologies that will boost these growth trends. The report provides a comprehensive overview including Definitions, Scope, Application, Production and CAGR (%)…
Global Vitamins Market 2019 - DSM, Lonza, CSPC, BASF
Vitamins are organic chemical compounds and a vital nutrient which an organism needs in minor quantities for the functioning of metabolism in the body. Vitamins cannot be synthesized in the body, but they can be consumed through food or supplements. Insufficient intake of vitamins may result in deficiency diseases and disorders such as night blindness, scurvy, and xerophthalmia.
Scope of the Report:
This report focuses on the Vitamins in global market, especially…
Genome Editing Market 2018, Merck KGaA, Genscript, Lonza
Global Genome Editing market 2018 by ReportsQuest presents a professional and complete analysis of on the current Industry situation. The Global report includes Genome Editing Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Genome Editing market players and the future prospects from various angles in detail. Industry analysis is a assessment tool used…
Molluscicides Market : Business methodologies 2028 | Lonza Group AG
Molluscicides Market: An Overview
Molluscicides are special type of pesticides which are used to kill mollusks, specifically slugs and snails. Of the various end users, demand for these pesticides continues to remain concentrated for agricultural and gardening industries. Molluscicides are sometimes referred as bait as they are also used to entice mollusks. When molluscicides are ingested or touched by the snail or slug, then the chemicals contained in molluscicides alter their…
Global Agarose Market 2018 - Lonza, Hispanagar, Biskanten, TSINGKE
Apex Market Reports, recently published a detailed market research study focused on the “Agarose Market” across the global, regional and country level. The report provides 360° analysis of “Agarose Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Agarose on the basis of…
